Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan‐omics precision. Issue 5 (14th February 2018)

• Record Type: Journal Article
• Authors: Hsieh, James J; Le, Valerie; Cao, Dengfeng; Cheng, Emily H; Creighton, Chad J
• Editors: Huntsman, David G; Ladanyi, Marc
• Is Part Of: Journal of pathology. Volume 244:Issue 5(2018)
• Page Start: 525
• Page End: 537
• Publication Date: 2018-02-14
• Subjects: renal cell carcinoma -- genomics -- transcriptomics -- proteomics -- metabolomics -- biomarkers -- targeted therapy -- precision therapeutics -- personalized medicine; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5022
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Over the past 20 years, classifications of kidney cancer have undergone major revisions based on morphological refinements and molecular characterizations. The 2016 WHO classification of renal tumors recognizes more than ten different renal cell carcinoma (RCC) subtypes. Furthermore, the marked inter‐ and intra‐tumor heterogeneity of RCC is now well appreciated. Nevertheless, contemporary multi‐omics studies of RCC, encompassing genomics, transcriptomics, proteomics, and metabolomics, not only highlight apparent diversity but also showcase and underline commonality. Here, we wish to provide an integrated perspective concerning the future 'functional' classification of renal cancer by bridging gaps among morphology, biology, multi‐omics, and therapeutics. This review focuses on recent progress and elaborates the potential value of contemporary pan‐omics approaches with a special emphasis on cancer genomics unveiled through next‐generation sequencing technology, and how an integrated multi‐omics approach might impact precision‐based personalized kidney cancer care in the near future. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.